Last reviewed · How we verify
Ezetimibe Tablets
Ezetimibe Tablets, marketed by NYU Langone Health, is a cholesterol-lowering medication with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, which differentiates it from other lipid-lowering therapies. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ezetimibe Tablets |
|---|---|
| Also known as | ZETIA |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) (PHASE3)
- Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides (PHASE4)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin (PHASE1)
- A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin (PHASE1)
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (PHASE4)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin (PHASE1)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin (PHASE1)
- Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ezetimibe Tablets CI brief — competitive landscape report
- Ezetimibe Tablets updates RSS · CI watch RSS
- NYU Langone Health portfolio CI